PURPOSE: The aim of this study was to assess the impact of fractionated total body irradiation (F-TBI) on treatment-related mortality (TRM) and relapse in patients who received a non-T-cell-depleted allogeneic stem cell transplantation (ASCT) for hematological malignancies. MATERIALS AND METHODS: Between March 2003 and December 2004, a total of 24 patients with HLA-identical sibling donors entered this study and received three doses of 3.33 Gy F-TBI separated by 24 h and cyclophosphamide or etoposide. RESULTS: At a median follow-up of 37 months (range 29-47 months), 4 of the 24 patients (16.6%) died of TRM. Relapse occurred in 10 patients at a median of 9 months (range 2-18 months). Overall, 13 of 24 patients (54%) died. Relapse was the most common cause of death (9/13). The 2-year actuarial survival rate was 46% (+/-11%). CONCLUSION: In our experience, ASCT conditioned with F-TBI was associated with low TRM but a high early relapse rate in patients with hematological malignancies.
PURPOSE: The aim of this study was to assess the impact of fractionated total body irradiation (F-TBI) on treatment-related mortality (TRM) and relapse in patients who received a non-T-cell-depleted allogeneic stem cell transplantation (ASCT) for hematological malignancies. MATERIALS AND METHODS: Between March 2003 and December 2004, a total of 24 patients with HLA-identical sibling donors entered this study and received three doses of 3.33 Gy F-TBI separated by 24 h and cyclophosphamide or etoposide. RESULTS: At a median follow-up of 37 months (range 29-47 months), 4 of the 24 patients (16.6%) died of TRM. Relapse occurred in 10 patients at a median of 9 months (range 2-18 months). Overall, 13 of 24 patients (54%) died. Relapse was the most common cause of death (9/13). The 2-year actuarial survival rate was 46% (+/-11%). CONCLUSION: In our experience, ASCT conditioned with F-TBI was associated with low TRM but a high early relapse rate in patients with hematological malignancies.
Authors: A Bacigalupo; V Vitale; R Corvò; S Barra; T Lamparelli; F Gualandi; N Mordini; G Berisso; S Bregante; A M Raiola; M T Van Lint; F Frassoni Journal: Br J Haematol Date: 2000-01 Impact factor: 6.998
Authors: T Lamparelli; M T Van Lint; F Gualandi; D Occhini; M Barbanti; N Sacchi; G Ficai; C Ghinatti; G B Ferrara; L Delfino; S Pozzi; A Morabito; P Zikos; V Vitale; R Corvo; F Frassoni; A Bacigalupo Journal: Bone Marrow Transplant Date: 1997-12 Impact factor: 5.483
Authors: E D Thomas; C D Buckner; R A Clift; A Fefer; F L Johnson; P E Neiman; G E Sale; J E Sanders; J W Singer; H Shulman; R Storb; P L Weiden Journal: N Engl J Med Date: 1979-09-13 Impact factor: 91.245
Authors: E D Thomas; R A Clift; J Hersman; J E Sanders; P Stewart; C D Buckner; A Fefer; R McGuffin; J W Smith; R Storb Journal: Int J Radiat Oncol Biol Phys Date: 1982-05 Impact factor: 7.038
Authors: R Corvò; T Lamparelli; B Bruno; S Barra; M T Van Lint; V Vitale; A Bacigalupo Journal: Bone Marrow Transplant Date: 2002-12 Impact factor: 5.483
Authors: E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden Journal: Blood Date: 1977-04 Impact factor: 22.113
Authors: T Girinsky; E Benhamou; J H Bourhis; F Dhermain; D Guillot-Valls; V Ganansia; M Luboinski; A Perez; J M Cosset; G Socie; D Baume; N Bouaouina; E Briot; A Beaudre; A Bridier; J L Pico Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544
Authors: V Vitale; A Bacigalupo; M T Van Lint; F Frassoni; G Ricci; G Siracusa; G Marziano; M L Vitali; G Scielzo; A Tomassini Journal: Br J Haematol Date: 1983-11 Impact factor: 6.998